Molecular Partners AG (MOLN) to collaborate with Novartis (NVS)

 Molecular Partners AG operates as a clinical-stage biopharmaceutical company.

  

• Sector(s): Healthcare
• Industry: Biotechnology
• Full Time Employees: 145
• Founded in 2004 
• HQ in Schlieren, Switzerland
• IPO: 6/16/21
• https://www.molecularpartners.com

Molecular Partners AG to collaborate with Novartis (NVS) to develop DARPin-conjugated radioligand therapeutic candidates for oncology

• Molecular Partners announced a collaboration with Novartis in the form of a license agreement to develop, manufacture and commercialize DARPin-conjugated radioligand therapies. The collaboration will combine Molecular Partners' industry-leading ability to rapidly generate high-affinity DARPins and the RLT capabilities and expertise of Novartis.
• Under the agreement, both parties will collaborate on the discovery and optimization of the therapeutic candidates. Novartis would be responsible for all clinical development and commercialization activities. Novartis will pay $20 million upfront to Molecular Partners, total potential development, regulatory and commercialization milestone payments of up to $560 million, and up to low double-digit percent of royalties.